Evidence map›Paper›PMID 41949781›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Prognostic value of the tumor immune microenvironment, PD-L1 and p16

August Fiegl, Miriam Angeloni, Jan Mink, Alexey Pryalukhin, Oybek Khalmurzaev, Stefan Lohse, João Lobo, Rui Henrique, Carmen Jerónimo, Hagen Loertzer and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

August FieglInstitute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany. august.fiegl@uk-erlangen.de.ORCID http://orcid.org/0009-0009-0633-1728
Miriam AngeloniInstitute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany.
Jan MinkDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Alexey PryalukhinInstitute of Clinical Pathology and Molecular Pathology, Wiener Neustadt State Hospital, Wiener Neustadt, Austria.
Oybek KhalmurzaevDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Stefan LohseInstitute of Virology, Saarland University, Homburg, Germany.
João LoboPortuguese Oncology Institute of Porto/Porto Comprehensive Cancer Center Raquel Seruca, & School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Rui HenriquePortuguese Oncology Institute of Porto/Porto Comprehensive Cancer Center Raquel Seruca, & School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Carmen JerónimoPortuguese Oncology Institute of Porto/Porto Comprehensive Cancer Center Raquel Seruca, & School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Hagen LoertzerClinic of Urology and Paediatric Urology, Westpfalz-Klinikum, Kaiserslautern, Germany.
Joachim SteffensDepartment of Urology and Paediatric Urology, Sankt-Antonius-Hospital, Eschweiler, Germany.
Heiko WunderlichClinic of Urology and Paediatric Urology Georg Klinikum, Eisenach, Germany.
Rainer M BohleInstitute of Pathology, Saarland University Medical Center, Homburg, Germany.
Michael StöckleDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Vsevolod MatveevDepartment of Urology, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation, Moscow, Russian Federation.
Carol GeppertInstitute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany.
Kerstin JunkerDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Fulvia FerrazziInstitute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany.
Arndt HartmannInstitute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Penile squamous cell carcinoma (PSCC) is a rare disease with limited systemic therapy strategies in advanced stages. To gain a better understanding about tumor and immune-related factors in PSCC with potential implications for future therapeutic options, we assessed T-lymphocytic tumor immune microenvironment (TIME), human papillomavirus (HPV) status, and p16 expression in a retrospective, multi-institutional cohort of 115 PSCC patients. We constructed a tissue microarray (TMA) containing cores from the tumor front (TF) and tumor center (TC) and performed immunohistochemistry (IHC) using antibodies against p16

Indexed as

Immune checkpoint therapyp16PD-L1Penile squamous cell carcinomaTumor infiltrating lymphocytesTumor microenvironment

Identifiers

PMID41949781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.